With the exception of nucleoside analogs, few direct acting antivirals in clinical development are active across the six major hepatitis C virus genotypes. We report novel consensus sequence chimeras for genotypes 2b, 3a, 4a, 5a, and 6a NS5B and show variable susceptibilities over a panel of NS5B inhibitors. Tegobuvir (GS-9190) had EC 50 s of o 16 nM against genotype 1 and 4100 nM for other genotypes tested here. An NS5B F445C mutation engineered into the GT3a, 4a, and 6a chimeric replicons lowered the tegobuvir EC 50 to levels comparable to those for genotype 1a, but did not considerably alter the EC 50 of site 2 or nucleoside analog inhibitors. These data support the use of HCV chimeras in profiling direct acting antivirals across genotypes and specifically determines the impact of the C445F NS5B polymorphism on tegobuvir potency against genotypes 3a, 4a, and 6a.
Introduction
Hepatitis C virus (HCV) infection is a global health concern with approximately 170 million individuals infected worldwide (Anon, 1999) . There are at least 6 main genotypes and multiple subtypes of HCV with the most common being genotype 1a in North America and Europe (Bukh et al., 1993; Simmonds et al., 2005) . It is estimated that genotypes 4, 5, and 6 account for 420% of infections worldwide (Antaki et al., 2010) . HCV infection may lead to serious liver diseases including liver fibrosis and cirrhosis, hepatic failure, and hepatocellular carcinoma. It is also the most common indication for liver transplantation; approximately 40-50% of patients on the liver transplant waiting list are infected with HCV (Brown, 2005) . The standard of care has been pegylated interferon-a and ribavirin (Pegþ RIBA) for 48 weeks. While this treatment leads to 80-90% sustained virologic response (SVR) in genotype 2 or 3 patients, there is only a 40-50% SVR rate in patients infected with HCV genotype 1 (Fried et al., 2002; Manns et al., 2001) . The recent approval of two new HCV NS3 protease inhibitors, telaprevir and boceprevir, in combination with PegþRIBA will increase SVR rates and shorten treatment durations, however they are only approved for genotype 1 HCV infection (Hofmann and Zeuzem, 2011; Jacobson et al., 2011; Poordad et al., 2011) .
Investigational agents targeting other HCV proteins such as the RNA dependent RNA polymerase NS5B have shown potent antiviral activity both in vitro and in vivo. NS5B inhibitors are typically divided into two classes: nucleoside analogs and nonnucleoside inhibitors (NNIs). Nucleoside analogs target the active site of NS5B and serve as chain terminators to prevent elongation and replication of the HCV RNA genome. NNIs are a more structurally diverse set of NS5B inhibitors targeting multiple sites on the NS5B polymerase. Nucleoside analogs generally have activity across multiple HCV genotypes as incorporation of a chain terminating base is indiscriminate of the polymerase genotype. In contrast, the available NNIs target at least 4 different allosteric sites on the NS5B polymerase (Legrand-Abravanel et al., 2010) . Site 1 and site 2 sit in the thumb domain of the polymerase. Site 2 inhibitors in phase 2 development include VX-222 (thiophene carboxylic acid) and filubivir (dihydroxypirone). Site 3 sits in the palm domain of the polymerase and is targeted by the Abbott compounds ABT333 and A-837093. Site 4 also sits in the palm domain and is targeted by the benzofuran HCV-796. Tegobuvir (GS-9190) is different in that it is considered a site 3/4 inhibitor. Since the NNIs target diverse sites on the polymerase there is sufficient amino acid variability in these regions to impact the potency of these compounds when compared across genotypes (Herlihy et al., 2008) .
Determining the antiviral potency of direct acting antiviral compounds targeted against the NS3 protease, NS5A, and the NS5B polymerase in HCV genotypes 3-6 has been hampered by the lack of complete and robust sub-genomic replicons or viral culture systems for these genotypes. Recently, several studies have been published establishing the use of chimeric replicons and viruses for specifically examining non-genotype 1 NS3, NS5A, and NS5B. Several factors likely contribute to the replication success or failure of these chimeras including the genotype of the vector backbone used and its compatibility or similarity with the chimeric genotype, the specific HCV gene to be studied, the site of genetic cross-over in the gene, and the representative sequence used for that gene. For the NS3 protease, chimeric replicons created on a 1b-con-1 backbone with the entire NS3/4A gene or NS3 protease alone from genotypes 2b, 3a, and 4 showed variable replication success (Binder et al., 2011) . In an infectious 2a(J6/JFH-1) based NS3/4A chimera system, only chimeras for genotypes 2a(J6), 3a, 5a, and 6a showed viral spread in transfected Huh7.5 cells . For NS5A, recombinant viruses were successfully established on the 2a (J6/JFH1) virus system with full length NS5A from genotypes 1-7 . For the HCV NS5B polymerase, chimeric replicons were successfully established on a 1b-con-1 backbone using NS5B sequences derived from patients for genotypes 2b, 3a, 4a, and 5a (Herlihy et al., 2008) . In all of these studies, HCV inhibitors displayed variable activity against chimeras dependent on the genotypes of the target genes and highlighted the utility of chimeric replicons and viruses.
Tegobuvir, a NS5B non-nucleoside polymerase inhibitor, has demonstrated potent activity against genotypes 1a and 1b HCV in vitro in HCV replicons, and in vivo in HCV genotype 1-infected patients (Lawitz et al., 2011; Shih et al., 2011) . Our current study aims to determine the antiviral activity of tegobuvir against HCV genotypes 2b, 3a, 4a, 5a, and 6a. A series of chimeric HCV replicons were constructed using both published sequences for these genotypes (Herlihy et al., 2008) as well as consensus sequences generated from NS5B sequences available in the EU and Los Alamos HCV databases. In addition to tegobuvir, we also examined NNIs targeting the site 2 thumb domain and the site 3 and 4 palm domain of NS5B. Furthermore, in genotype 1b, the C445F mutation is reported to cause a 7.1 fold increase in EC 50 (Shih et al., 2011) . This amino acid position is polymorphic between genotype 1 and genotypes 2-6. In genotypes 1a and 1b, the NS5B 445 amino acid is cysteine, while in genotypes 2-6, the residue is phenylalanine. To further characterize this polymorphism's role in tegobuvir potency versus different genotypes, the NS5B phenylalanine at position 445 in our genotype 2b, 3a, 4a, 5a, and 6a chimeras were mutated to match the genotype 1 cysteine residue (F445C) and assessed for tegobuvir susceptibility.
Results

Construction and replication capacity of NS5B genotype chimeras
A HCV 1b-con-1 subgenomic replicon was used as the base for construction of NS5B chimeras. This replicon also contains the Renilla luciferase gene and is designated as 1b-hRLuc. The last 413 base pairs (encoding the last 137 NS5A amino acids) of 1b-con-1 NS5A were synthesized in frame with NS5B from reported sequences for NS5B derived from patient isolates (Herlihy et al., 2008) with HCV genotype (GT) 2b, 3a, 4a, 5a, and 6a infections. The 3 0 -UTR from 1b-con-1 remained intact and the resultant chimeras were identical to the 1b-con-1 sequence except for the region encoding NS5B (Fig. 2) . This series of chimeras is designated as ''clinical isolates'' (CI) hereafter. In addition to using the NS5B sequences found in Herlihy et al. (2008) , a consensus sequence was derived by multiple alignment using NS5B sequences available in the EU Database for HCV genotypes 2b, 3a, 4a, 5a, and 6a (Supplemental Table 1 ). Multiple alignment of the primary amino acid sequence among these new consensus sequences with those for 1a-H77, 1b-con-1, and 2a-JFH1 showed greater than 74% identity across genotypes (Table 1 ). The NS5B consensus for each of these genotypes was also synthesized in frame with the 413 bp of 1b-con-1 NS5A and the entire cassette was cloned into the 1b-hRLuc/NeoR NS5B shuttle vector as described above. This series of chimeras is designated as ''consensus'' (Con) hereafter.
To test the replication capacity of these chimeras, replicon RNA was transiently transfected into Huh7-lunet cells and luciferase activity was measured at 4 and 72 h post transfection. These results are summarized in Fig. 3 . For GT2b CI and Con chimeras, replication capacity was similar with luciferase readings near 1000. Both GT4a chimeras also replicated well with the GT4a Con chimera replicating to a higher level than the GT4a CI chimera. In contrast, the GT3a and GT6a Con chimeras replicated well while the GT3a and GT6a CI chimeras did not replicate above background luciferase levels; this is consistent with results reported by Herlihy et al. for these CI chimeras. The opposite was observed for GT5a chimeras; the CI chimera replicated well, but replication capacity was lost in the Con chimera. For the genotype 3a, 5a, and 6a chimeras, the NS5B amino acid differences between the CI and Con chimeras were 9, 20, and 19 residues, respectively (Supplemental Table 2 ). For all of the Con NS5B chimeras except GT5a, stable cell lines were generated by serial passaging of transfected cells with G418 in cell culture. A cell line was also established by G418 selection for the GT5a CI chimera.
NS5B chimera susceptibility to HCV polymerase inhibitors
To determine the susceptibility of the NS5B chimeras to tegobuvir (GS-9190) and other NS5B inhibitors acting on diverse sites in the polymerase, stable cell lines harboring chimeric replicons were treated with either, tegobuvir, the benzimidazole site 1 NNI JT-16, a thiophene carboxylic acid site 2 NNI, the benzofuran site 4 NNI HCV-796, the benzothiadiazine site 3 NNI A-837093, or the nucleoside inhibitor 2 0 -C-Methyl-Adenosine (Fig. 1) . Table 2 shows the EC 50 (nM) for all compounds tested against the 1b-con-1 replicon and the fold shift in EC 50 for the other compounds compared to 1b-con-1. Consistent with previous data, tegobuvir is the most potent versus the 1b-con-1 replicon with an approximately 10 fold lower shift in EC 50 against the 1a-H77 replicon (Shih et al., 2011) . Treatment of 2a-JFH1 replicon and GT3a, 4a, 6a-Con, and 5a CI chimeras produced fold shifts varying from 57 to 14,700 less susceptibility to tegobuvir.
For other NNIs tested, the benzimidazole site 1 NNI JT-16 had fold shifts in EC 50 compared to 1b-con-1 ranging from none (1.0) for GT5a to 144 fold for GT2b. The thiophene carboxylic acid site 2 inhibitor had fold shifts in susceptibility ranging from a low 9.0 fold versus the GT5a CI and a high of 3160 fold shift versus the 2a-JFH1 replicon. The benzothiadiazine A-837093 NS5B site 3 inhibitor only showed single digit nanomolar EC 50 s against GT1b and GT1a replicons. Fold shifts for this compound ranged from a low of 105 fold against GT4a Con to a high of 3398 fold against the 2a-JFH1 replicon. In contrast to the other NNIs, the benzofuran HCV-796 NS5B site 4 inhibitor had the least amount of EC 50 variability across the genotypes tested, with the highest fold shift being 18.4 fold versus the 2a-JFH1 replicon. The EC 50 of HCV-796 was decreased by nearly 10 fold against GT5a CI when compared to 1b-con-1.
The active site nucleoside inhibitor 2 0 -C-Methyl-Adenosine was also tested across the NS5B genotypes. This nucleoside analog showed similar potency across genotypes tested with the highest EC 50 fold shift of 2.1 versus the 2a-JFH1 replicon. As a control, an HCV NS3 protease inhibitor was assayed and showed minimal fold shifts across the NS5B chimeras consistent with the chimeras all containing the 1b-con-1 NS3 protease (Table 2) .
Tegobuvir potency is reduced in GT3a, 4a, and 6a by the F445 polymorphism
Resistance selection with tegobuvir in 1b-con-1 replicon identified several mutations contributing resistance, including C316Y, C445F, Y448H, and Y452H (Shih et al., 2011 Fig. 2 . Cloning of NS5B chimeric replicons. A genotype 1b HCV subgenomic NS3-NS5B replicon with bi-cistronic expression of the Renilla luciferase and neomycin resistance genes was used as the backbone for construction of NS5B chimeras. This replicon contains an internal deletion in NS5B rendering it replication deficient (D5B). GT1b NS5A was synthesized from the indicated unique XhoI site to the junction with NS5B; at which point the DNA sequence for C.I. or Con NS5B from GTs 2b, 3a, 4a, 5a, and 6a was synthesized through the stop codon and unique AseI site. XhoI-AseI cassettes containing the in-frame GT1b-(NS5A) to GTx-(NS5B) were cloned into the base replicon via the unique XhoI and AseI sites. Table 1 NS5B amino acid identity across HCV genotypes. The primary amino acid sequence for NS5B from HCV 1a-H77, 1b-con-1, 2a-JFH1, 2b-Con, 3a-Con, 4a-Con, 5a-Con, and 6a-Con were aligned by AlignX (Vector NTi). Amino acid identities were compared across genotypes and the percent of identical residues were calculated pairwise.
1a H77 1b Con 2a JFH1 2b Con 3a Con 4a Con 5a Con 6a Con Fig. 3 . Replication capacity of NS5B chimeras. Replication capacity was measured for both the clinical isolate (CI) and consensus (Con) NS5B chimeras by transient transfection into Huh7-lunet cells followed by measurement of Renilla luciferase activity 72 h post transfection. The log 10 relative luciferase units were plotted for all the replicons tested. 1b-con-1 was used as a positive control. Light shaded bars are luciferase activity from CI chimeras and dark shaded bars are from Con chimeras. Dashed line represents background luciferase reading for no transfection control.
these mutations have been detected in the clinic from patients treated with tegobuvir Mo et al., 2011) . Mutation at NS5B position C316 is a site of cross resistance for tegobuvir and HCV-796. HCV-796 has been reported to have a 166 fold shift in EC 50 to the C316Y mutation and a 26 fold shift to C316N mutation (Howe et al., 2008) . For comparison, the fold shift in EC 50 for the C316Y and C316N mutations against tegobuvir are 9 (Shih et al., 2011) and 5 fold respectively. Multiple alignments of the NS5B amino acid sequences across genotypes allowed us to determine if any of these resistance mutations were present as amino acid polymorphisms in other genotypes. For genotypes examined here, NS5B amino acids C316, Y448, and Y452 remained unchanged compared to 1b-con-1. In contrast, C445F was present in genotypes 2a, 2b, 3a, 4a, 5a, and 6a. To determine if the C445F polymorphism contributes to the reduced potency of tegobuvir in genotypes 2-6, the residues were changed by site directed mutagenesis to cysteine (F445C) in the chimeric replicons to match that of HCV genotype 1. The F445C mutants were transfected into Huh7-lunet cells and luciferase was read at 4 h and 72 h post transfection. The 2b and 5a F445C mutants did not replicate, however, the 3a F445C mutant replicated with an average relative luciferase unit reading of 17,449 at 72 h post transfection. The 4a and 6a F445C mutants had luciferase readings between 400-1000 at 72 h post transfection (data not shown). Selection of stable cell lines with G418 was successful for F445C cell lines of genotypes 3a, 4a, and 6a Con. Tegobuvir, 2 0 C-Me-A, and the thiophene carboxylic acid susceptibility was tested against these three F445C cell lines and compared to the GT1a-H77 and 1b-con-1 replicons, and the HCV genotype 3a, 4a, and 6a Con chimeras (Fig. 4) . Tegobuvir was potent in GT1a and 1b with mean EC 50 s of 19.8 and 1.5 nM respectively. For genotype 3a, 4a, and 6a Con chimeras, tegobuvir EC 50 s were all greater than 100 nM. The F445C NS5B mutations in GT3a, 4a, and 6a chimeric replicons restored tegobuvir potency to EC 50 levels comparable to GT1a. These increases in susceptibility for the F445C mutations were not seen with the nucleoside inhibitor 2 0 -C-Me-A or the thiophene carboxylic acid NS5B site 2 inhibitor (Fig. 4) .
Discussion
This study utilized NS5B chimeric replicons to assess the potency of the NS5B inhibitor tegobuvir in HCV genotypes 2b, 3a, 4a, 5a, and 6a. Several studies have used chimeric HCV replicons or viruses to characterize drug susceptibility of HCV genotypes for which full length replicons or viruses were not available; however, to our knowledge, this is the first study that has successfully used a NS5B GT6a chimeric replicon. In comparison to the non-replicating GT6a CI chimera, the consensus sequence-derived GT6a Con chimera differs at only 19 amino acid positions across the NS5B coding region. Transient replication assays show that the GT3a Con chimera had a 75 fold increase in replication capacity compared to the GT3a CI chimera. The difference in amino acid identity was only 9 residues in NS5B when comparing the GT3a chimeras. Any one or combination of these differing residues may be responsible for the ability of the GT3a and GT6a Con chimeras to replicate better than their respective CI chimeras. Conversely, the GT5a Con chimera did not Table 2 Comparison of anti-viral activity of tegobuvir and other known HCV NS5B inhibitors against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a. EC 50 values in nM were determined for 1a-H77, 1b-con-1, and 2a-JFH1 full replicons and 2b-Con, 3a-Con, 4a-Con, 5a-CI, and 6a-Con stable chimeric replicon cell lines. Fold changes in EC 50 were calculated against the 1b-con-1 EC 50 value. Results represent the average of at least 2 independent experiments. Fig. 4 . The NS5B F445C mutation restores tegobuvir potency against HCV GT3a, 4a, and 6a. EC 50 (nM) is plotted for tegobuvir, 2 0 -C-Methyl-Adenosine, and the thiophene carboxylic acid for GT1a and 1b replicons and 3a, 3a F445C, 4a, 4a F445C, and 6a, 6a F445C chimeric replicons. EC 50 values are calculated from at least 2 independent experiments. replicate while the GT5a CI chimera did. The amino acid differences between NS5B in these two chimeras is 20 amino acids; similarly any one or combination of differences may be responsible for the lack of replication of the GT5a Con chimera (Supplemental Table 2 ). In this study, we have taken the approach of using a 1b-con-1 replicon backbone and cloned in NS5B from diverse genotypes. In a study by Muryama et al., genotype 2aJFH-1 and 2aJ6 replicons were used to create a series of chimeras. A 2aJFH-1 backbone chimera with a 2aJ6 NS5Bþ3 0 UTR was replication deficient whereas the same chimera with only the coding sequence for NS5B 2aJ6 replicated but had a more than 100-fold reduction in replication capacity (Murayama et al., 2007) . Due to the loss of replication capacity, even when exchanging NS5B for another sequence in the same 2a genotype, we chose not to pursue the generation of NS5B chimeras using 2aJFH-1 as the replicon backbone.
One restriction of the current study is the limited analysis of subtypes within a given HCV genotype. There are clearly differences in susceptibility to direct acting antivirals among subtypes as evidenced by the different fold shifts in EC 50 observed in our study between genotypes 1b and 1a and between genotypes 2a and 2b. Nevertheless, in the absence of full replicons for less common subtypes, a chimeric replicon approach could be succesfully employed to analyze additional HCV NS5B subtypes.
Overall, fold shifts in antiviral potency versus 1b-con-1 of a site 1 benzimidazole (JT-16), a site 2 thiophene carboxylic acid, site 3 benzothiadiazine (A-837093), a site 4 benzofuran (HCV-796), and a nucleoside inhibitor (2 0 -C-Me-A) were comparable to those reported previously in HCV genotypes 1-5 (Herlihy et al., 2008) . Against the GT6a Con chimera, we measured an 11.6 fold shift in EC 50 over GT1b for the site 1 inhibitor JT-16, a 673 fold shift for the thiophene carboxylic acid site 2 inhibitor, and a 3470 fold shift with the site 3 inhibitor A-837093. Consistent with the broader genotypic activity of active site nucleoside inhibitors and HCV-796, the GT6a Con chimera was susceptible to both of these classes of inhibitors within a 2-fold change from the 1b-con-1 susceptibility (Table 2) .
Tegobuvir is currently being studied in combination with other direct acting antivirals for treatment of chronic genotype 1 HCV infection in several Phase 2 clinical studies. We determined the EC 50 of tegobuvir against GT2b, 3a, 4a, 5a, and 6a NS5B chimeras to evaluate its potency in non-genotype 1 replicon systems. Tegobuvir potency against non-genotype 1 replicons generally fell into two categories, highly resistant or moderately resistant. The first group consisted of genotypes 2a, 2b, 3a, and 4a with fold shift increases in EC 50 ranging from 661 to 14,700. The moderately resistant genotype 5a and 6a replicons had tegobuvir EC 50 fold shifts of 69 and 57 respectively (Table 2) . It is interesting to note that the lowest tegobuvir fold shift was observed with GT6a Con, where the NS5B sequence is 80% identical to 1a-H77 and 1b-con-1 (Table 1) . This is the highest amino acid identity between GT1 and the non-GT1 NS5B sequences used in this study. However, this trend was not consistent with the other NNIs tested here suggesting that specific polymorphic residues or combinations of residues impact NNI potency rather than the overall percent identity to GT1.
In GT2-6 NS5B chimeras, the fold shift in EC 50 was high for tegobuvir. Non-genotype 1 HCV all possess phenylalanine at NS5B position 445 in contrast to the cysteine in GT1a and 1b at the same position. Mutation of F445 to C445 in the chimeras resulted in replication competent subgenomic replicons for only GT3a, 4a, and 6a. This single amino acid change in these chimeras significantly reduced the EC 50 for tegobuvir 410 fold when compared to their wild-type chimeras. Although this potency increase did not bring the tegobuvir susceptibility down to the level of 1b-con-1, it was comparable to the EC 50 for 1a-H77 replicon (16 nM). These data indicate that a major factor in the lack of tegobuvir susceptibility in GT3a, 4a, and 6a replicons can be attributed to their NS5B F445 polymorphism when compared to GT1. A query of the EU HCV sequence database for GT3a, 4a, and 6a at NS5B position 445 shows phenylalanine as 100% conserved in those genotypes. The 1b-con-1 C445F site directed mutant fold shift in EC 50 is approximately 10 compared to 1b-con-1 (Shih et al., 2011) ; this is significantly lower than the wild-type GT3a, 4a, and 6a Con chimera fold shifts to 1b-con-1 listed in Table 2 . Therefore, other residues beyond F445 within NS5B must contribute as well to the overall susceptibility to tegobuvir because the 1b-con-1 C445F mutant EC 50 is significantly lower than those for GT3a, 4a, and 6a. Further examination of the role that NS5B residue C445 or F445 plays across genotypes in the interaction with tegobuvir is warranted.
Determining direct acting antiviral activity against diverse HCV genotypes has been challenging without the availability of full replicons or virus systems for HCV GTs 3-6. Use of a chimeric replicon system has been successfully employed in this study and others to characterize DAA activity against diverse HCV genotypes and subtypes (Binder et al., 2011; Herlihy et al., 2008) . A new standard of care has been set with the approvals of the NS3 protease inhibitors telaprevir and boceprevir; however, these drugs are only effective against GT1 HCV infections. Going forward, tools to assess activity among HCV genotypes and understanding why compounds are potent in one and not another will be critical to achieve the ultimate goal of creating oral small molecule pan-genotype HCV DAAs capable of achieving high SVR rates across genotypes.
Materials and methods
Chimera construction
A 1b-con-1 Renilla luciferase expressing replicon was used as a backbone for chimera construction. This replicon contained an internal deletion in NS5B rendering it replication deficient. The last 413 base pairs (encoding last 137 NS5A amino acids) of 1b-con-1 NS5A were synthesized in frame with NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a (Genscript Inc. Piscataway NJ). Consensus NS5B sequences for each of these genotypes were derived by aligning sequences deposited in the European HCV database and extracting a consensus. These novel consensus sequences for NS5B as well as sequences derived from individual clinical isolates (Herlihy et al., 2008) were used to construct the NS5B chimeric replicons. A unique XhoI site was used at the 5 0 end and a unique AseI site at the 3 0 end to directionally clone into the 1b-hRLuc/NeoR NS5B vector via standard molecular biology techniques.
Transient transfection and cell culture
DNA plasmids encoding full and chimeric replicons were linearized by overnight SpeI (New England Biolabs, Ipswich, MA) restriction digest. Digested DNA was purified by QIAquick column purification (Qiagen, Valencia, CA). Replicon RNA was subsequently transcribed using a T7 MEGAscript kit (Ambion, Carlsbad, CA). For transfection into Huh-7 Lunet cells, cells were trypsinized and washed two times in cold PBS. A suspension of 4 Â 10 6 cells in 400 mL cold PBS was mixed with 2 mg RNA in 4 mm gap width electroporation cuvette and pulsed at 270 V and 950 mF capacitance. Cells were transferred into complete cell culture medium and seeded into appropriate plates for further analyses.
Cell lines
Huh-7-Lunet cells were obtained from ReBlikon GmbH (Mainz, Germany). All cells were cultured in complete cell culture medium [Dulbecco's Modified Eagle's Medium (DMEM) with GlutaMAX-I (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT) 1 U/mL penicillin, 1 mg/mL streptomycin, and 0.1 mM non-essential amino acids (Invitrogen)]. Stable 1b-con-1, 1a-H77, and 2a-JFH1 cells have been reported previously (Lohmann et al., 1999; Robinson et al., 2010; Shih et al., 2011) . To select stable chimeric replicon cells, transfected cells were switched to G418 (Geneticin, Invitrogen) containing media approximately 24 h following transfection.
G418 concentration was started at 400 mg/mL but selective pressure was lowered to 200 mg/mL for the GT3a replicon cell line with lower replication level. Cells were continually cultured in G418 containing media.
Compounds
Tegobuvir (GS-9190), JT-16, and the thiophene carboxylic acid site 2 inhibitor were synthesized at Gilead Sciences, Inc. (Foster City, CA.). HCV-796 was synthesized by Curragh Chemistries (Cleveland, OH). A-837093 was synthesized by ChemALong Laboratories (Lemont, IL). 2 0 -C-methyl adenosine was purchased from Acme Biosciences (Belmont, CA) (Fig. 1) .
Antiviral EC 50 determination
Stable replicon cells were trypsinized and seeded in complete cell culture media in black 96-well plates at 4000 cells/well for EC 50 determinations. Nine point dilutions of compounds were performed in DMSO followed by 1:100 dilutions in complete cell culture medium for subsequent addition to cell plates. Compound treatments were for 72 h at 37 1C in a 5% CO 2 humidified incubator. Luciferase activity was measured using the Renilla Luciferase Assay System (Promega, Madison, WI) in a Victor X luminometer (PerkinElmer, Waltham, MA). Non-linear regression and curve fitting to determine EC 50 was calculated using Graphpad Prism (Graphpad Software, Inc., La Jolla, CA).
